We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




High Homocysteine Levels Linked to Alzheimer's

By Biotechdaily staff writers
Posted on 21 May 2002
A new study has found that people with elevated levels of homocysteine in the blood have nearly twice the risk of developing Alzheimer's disease (AD) vs people with normal levels. More...
The findings were reported in the February 14, 2002, issue of The New England Journal of Medicine.

The study was conducted by researchers at Boston University (MA, USA) and Tufts University (also in Boston), based on data on 1,092 dementia-free participants. The participants, whose average age was 76, were enrolled in 1976-78. Their plasma homocysteine levels were measured in 1979-1982 and in 1986-1990. Age, sex, vascular risk factors other than homocysteine, and plasma levels of folate and vitamins B6 and B12 were also considered, as was late-onset genetic risk factor APOE-epsilon4.

Exams from 1986-1990 through December 2000 revealed that 111 people had developed dementia, including 83 diagnosed with AD. Elevated homocysteine levels, defined as greater than 14 micro-mol/l, doubled the chance that a participant would develop AD, and each 5 micro-mol/l elevation increased the risk by 40%. The analysis showed that people with consistently high levels throughout the study period were at highest risk for dementia and AD. The analysis also linked elevated levels at least eight years prior to a later diagnosis of dementia and AD. The association was strong and independent of all other factors considered. No direct association was found in this study between the development of dementia and serum levels of folate and vitamins B6 and B12 in subjects.

"The good news is that we may have found a potential risk factor for AD that is modifiable,” said Neil Buckholtz, Ph.D., chief of the Dementias of Aging program at the US National Institute on Aging. "We don't know yet whether reducing homocysteine levels will reduce dementia risk, but this is something that can and will be tested in clinical trials.”




Related Links:
Boston University
Tufts University

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.